Description

BRAVECTO 250 MG for Dogs Weighing 4.5 kg to 10 kg

Indications

BRAVECTO 250 MG is an oral chewable tablet indicated for the treatment and prevention of flea infestations and the control of tick infestations in dogs weighing between 4.5 kg and 10 kg. This product is effective against various species of ticks, including the Ixodes ricinus (castor bean tick), Rhipicephalus sanguineus (brown dog tick), and Dermacentor variabilis (American dog tick). BRAVECTO provides long-lasting protection, with a single dose offering up to 12 weeks of efficacy against fleas and ticks.

Mechanism of Action

The active ingredient in BRAVECTO is fluralaner, which belongs to the isoxazoline class of compounds. Fluralaner works by inhibiting the function of the insect nervous system. It selectively targets the GABA-gated chloride channels and the glutamate-gated chloride channels in arthropods, leading to hyperexcitation of the nervous system and ultimately resulting in the death of fleas and ticks. This mode of action ensures that BRAVECTO is effective in eliminating existing infestations and preventing new ones.

Pharmacological Properties

BRAVECTO is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 8 hours. The bioavailability of fluralaner is high, allowing for effective systemic distribution throughout the body. The elimination half-life of fluralaner in dogs is approximately 12 days, which supports its extended duration of action. Fluralaner is primarily metabolized in the liver and excreted via feces, with minimal renal excretion. This pharmacokinetic profile contributes to the long-lasting effects of BRAVECTO, making it a convenient option for pet owners.

Contraindications

BRAVECTO should not be administered to dogs that are hypersensitive to fluralaner or any of the excipients in the formulation. It is also contraindicated in puppies younger than 8 weeks of age or those weighing less than 2 kg. Additionally, the use of BRAVECTO is not recommended in breeding, pregnant, or lactating dogs unless the benefits outweigh the risks, and it should only be prescribed under veterinary guidance in such cases.

Side Effects

BRAVECTO is generally well-tolerated by dogs, with most side effects being mild and transient. Common side effects may include vomiting, diarrhea, lethargy, and decreased appetite. In rare cases, more severe reactions such as hypersensitivity, seizures, or neurological signs may occur. If any adverse reactions are observed, it is essential to contact a veterinarian immediately for evaluation and management. Regular monitoring after administration can help ensure the safety and well-being of the pet.

Dosage and Administration

The recommended dosage of BRAVECTO for dogs weighing between 4.5 kg and 10 kg is one 250 MG chewable tablet, administered orally with food to enhance absorption. For optimal results, it is advisable to administer the tablet at approximately the same time every 12 weeks. If a dose is missed, it should be given as soon as possible, but if it is close to the time for the next dose, the missed dose should be skipped, and the regular dosing schedule resumed. Overdosing should be avoided, and any concerns regarding dosage should be discussed with a veterinarian.

Interactions

Currently, there are no known significant drug interactions with BRAVECTO. However, caution should be exercised when administering other medications concurrently, especially those that also affect the central nervous system or have similar pharmacological properties. It is essential to inform the veterinarian of all medications and supplements the dog is currently receiving to ensure safe and effective treatment.

Precautions

Before administering BRAVECTO, a thorough veterinary examination is recommended to rule out any underlying health issues that may contraindicate its use. Special care should be taken in dogs with a history of seizures or neurological disorders, as fluralaner may exacerbate these conditions. Additionally, pet owners should observe their dogs for any signs of adverse reactions following administration, particularly during the first few days after treatment. Regular veterinary check-ups are advised to monitor the dog’s health and the effectiveness of the flea and tick control program.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of BRAVECTO in controlling flea and tick infestations in dogs. In a pivotal study, BRAVECTO was shown to achieve over 98% efficacy against fleas within 12 hours of administration and maintained this efficacy for up to 12 weeks. In another study, BRAVECTO demonstrated significant effectiveness against various tick species, with rapid kill times and sustained protection. These studies support the use of BRAVECTO as a reliable option for flea and tick control in dogs.

Conclusion

BRAVECTO 250 MG is a highly effective oral treatment for the prevention and control of flea and tick infestations in dogs weighing between 4.5 kg and 10 kg. With its long-lasting effects and convenient dosing schedule, BRAVECTO provides pet owners with a practical solution for maintaining their dog’s health and comfort. As with any medication, it is crucial to follow the recommended guidelines and consult with a veterinarian to ensure the safe and effective use of BRAVECTO.